AbbVie is committed to the pursuit of innovative, effective solutions for dermatology diseases with unmet needs.

Will you be attending EADV conference?

Our Vision for the Future

Building on a strong foundation of historical success, we’re striving to uncover new opportunities to target immune-mediated inflammatory dermatological diseases at their source, revolutionizing treatment to free the world of debilitating skin conditions. After more than a decade of research, we’ve developed unique technologies to optimize therapeutics in the area of dermatology, and we’re focused on diseases where treatment options are scarce or non-existent.

Leading the Way

The Road Ahead

Commitment to Patients

We have a bold vision for the future: one where we have an answer for even more patients. Years of clinical studies have revealed a greater need for medical solutions to accommodate a diverse community of patients.

The Road Ahead

The Road Ahead

Guided by real patient journeys, we’re investigating three immune-mediated dermatological conditions—searching relentlessly for the best path forward. Our commitment continues with long-term investments in developing label enhancements for approved products, innovation in patient support, and a focus on high-quality education for both patients and physicians.

New Pathways

New Pathways

Our pipeline currently features two late-stage investigational compounds for dermatology patients. One is a biologic that selectively blocks IL-23, an agent linked to psoriasis and psoriatic arthritis. Another, an oral JAK1-selective inhibitor, is being explored as a new treatment for patients with atopic dermatitis and psoriatic arthritis.

Our Pathways

TNF- α

A cytokine that contributes to the induction and maintenance of the inflammatory immune response.
Learn more about related assets in our Pipeline


An enzyme partially responsible for inappropriate activation of immune cells involved in autoimmune disorders.
Learn more about related assets in our Pipeline


A key protein involved in skin inflammation which has been linked to an overactive immune system.
Learn more about related assets in our Pipeline


A protein that regulates the production of other key pro-inflammatory proteins.
Learn more about related assets in our Pipeline

Committed to Dermatology

Calendar Icon

EADV 2017

This year, we’re excited to share AbbVie’s latest developments for hidradenitis suppurativa (HS) and psoriasis at Europe’s premier scientific event for developments in dermatology. Here’s what we’ll be up to while we’re there:

  • Showcasing the patient journey and capturing attendees’ passion through our exhibit
  • Featuring 17 abstracts throughout the Congress
  • Participating in the PS Symposium on Thursday, Sept. 14 (Hall 1 Room 3, from 5-6:30 p.m.)
  • Participating in the HS Symposium on Friday, Sept. 15 (Hall 1 Room 3, from 5-6:30 p.m.)
News Icon

In the News

AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis
Read More

U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA® (adalimumab) Prescribing Information
Read More

AbbVie's HUMIRA:registered: (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Read More


Our team of immunology experts is focused on improving the standard of care for this generation and the next. We’re pioneers, builders and innovators; and we’re hiring.


Science Rocks! Gut Instincts that Help Us Understand Our Health

Get the Latest from AbbVie

Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.

This site uses cookies to personalize content, save your preferences and track the site’s performance. Learn more, including how to disable certain cookies on our Privacy Page. Click OK to continue.